1887

Abstract

This study was planned to evaluate the efficacy of silver nitrate and gentamicin in the treatment of burn wound infection and to compare it with phage therapy using an isolated and well-characterized -specific phage, Kpn5. A full-thickness burn wound was induced in mice and infected with B5055 via the topical route. Different concentrations of silver nitrate or gentamicin were applied topically daily after establishment of infection. Phage Kpn5 mixed in hydrogel was also applied topically at an m.o.i. of 200 on the burn wound site. The efficacy of these antimicrobial agents was assessed on the basis of percentage survival of infected mice following treatment. The results showed that a single dose of phage Kpn5 resulted in a significant reduction in mortality (<0.001). Daily applications of silver nitrate and gentamicin at 0.5 % and 1000 mg l, respectively, provided significant protection (<0.001) compared to lower concentrations of the two agents. However, the level of protection given by these two agents was lower than that given by the phage therapy. The results strongly suggest that phage Kpn5 has therapeutic utility in treating burn wound infection in mice as a single topical application of this phage was able to rescue mice from infection caused by B5055 in comparison to multiple applications of silver nitrate and gentamicin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.018580-0
2011-02-01
2019-12-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/2/205.html?itemId=/content/journal/jmm/10.1099/jmm.0.018580-0&mimeType=html&fmt=ahah

References

  1. Adams, M. H. ( 1959; ). Bacteriophages, pp. 450–456. New York. : Interscience Publishers.
    [Google Scholar]
  2. Atkinson, B. A. ( 1980; ). Species incidence, trends of susceptibility to antibiotics in the United States and minimum inhibitory concentration. In Antibiotics in Laboratory Medicine, pp. 607–722. Edited by Lorian, V.. Baltimore. : Williams & Wilkins.
    [Google Scholar]
  3. Basketter, D. A., York, M., McFadden, J. P. & Robinson, M. K. ( 2004; ). Determination of skin irritation potential in the human 4-h patch test. Contact Dermatitis 51, 1–4.[CrossRef]
    [Google Scholar]
  4. Bedi, M. S., Verma, V. & Chhibber, S. ( 2009; ). Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotechnol 25, 1145–1151.[CrossRef]
    [Google Scholar]
  5. Bradbury, J. ( 2004; ). “My enemy's enemy is my friend.” Using phages to fight bacteria. Lancet 363, 624–625.[CrossRef]
    [Google Scholar]
  6. Chhibber, S., Kaur, S. & Kumari, S. ( 2008; ). Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 57, 1508–1513.[CrossRef]
    [Google Scholar]
  7. Chopra, I. ( 2007; ). The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicrob Chemother 59, 587–590.[CrossRef]
    [Google Scholar]
  8. Church, D., Elsayed, S., Reid, O., Winston, B. & Lindsay, R. ( 2006; ). Burn wound infections. Clin Microbiol Rev 19, 403–434.[CrossRef]
    [Google Scholar]
  9. Cook, N. ( 1998; ). Methicillin resistant Staphylococcus aureus versus the burned patient. Burns 24, 91–98.[CrossRef]
    [Google Scholar]
  10. Cooper, J. W. ( 1989; ). Cooper and Gunn's Dispensing for Pharmaceutical Students, 12th edn. Edited by Carter, S. J.. Edinburgh. : Churchill Livingstone.
    [Google Scholar]
  11. Dale, R. M. K., Schnell, G. & Wong, J. P. ( 2004; ). Therapeutic efficacy of “Nubiotics” against burn wound infection by Pseudomonas aeruginosa. Antimicrob Agents Chemother 48, 2918–2923.[CrossRef]
    [Google Scholar]
  12. Dunn, K. & Edwards-Jones, V. ( 2004; ). The role of ActicoatTM with nanocrystalline silver in the management of burns. Burns 30, S1–S9.[CrossRef]
    [Google Scholar]
  13. Erol, S., Altoparlak, U., Akcay, M. N., Celebi, F. & Parlak, M. ( 2004; ). Changes of microbial flora and wound colonization in burned patients. Burns 30, 357–361.[CrossRef]
    [Google Scholar]
  14. Fox, C. L., Jr ( 1968; ). Silver sulphadiazin: a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg 96, 184.[CrossRef]
    [Google Scholar]
  15. Górski, A., Targońska, M., Borysowski, J. & Weber-Dąbrowska, B. ( 2009; ). The potential of phage therapy in bacterial infections of the eye. Ophthalmologica 223, 162–165.[CrossRef]
    [Google Scholar]
  16. Hanlon, G. W. ( 2007; ). Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30, 118–128.
    [Google Scholar]
  17. Heggers, J. P., Sazy, J. A., Stenberg, B. D., Strock, L. L., McCauley, R. L., Herndon, D. N. & Robson, M. C. ( 1991; ). Bactericidal and wound-healing properties of sodium hypochlorite solutions: the 1991 Lindberg Award. J Burn Care Rehabil 12, 420–424.[CrossRef]
    [Google Scholar]
  18. Inal, J. M. ( 2003; ). Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp (Warsz) 51, 237–244.
    [Google Scholar]
  19. Ip, M., Lui, S. L., Poon, V. K. M., Lung, I. & Burd, A. ( 2006; ). Antimicrobial activities of silver dressings: an in vitro comparison. J Med Microbiol 55, 59–63.[CrossRef]
    [Google Scholar]
  20. Kapoor, N., Chhibber, S. & Vadehra, D. V. ( 1989; ). Susceptibility of multidrug-resistant isolates of Klebsiella pneumoniae to silver nitrate. Folia Microbiol (Praha) 34, 94–98.[CrossRef]
    [Google Scholar]
  21. Kumari, S., Harjai, K. & Chhibber, S. ( 2009; ). Efficacy of bacteriophage treatment in murine burn wound infection induced by Klebsiella pneumoniae. J Microbiol Biotechnol 19, 622–628.
    [Google Scholar]
  22. Lansdown, A. B. ( 2005; ). A guide to the properties and uses of silver dressings in wound care. Prof Nurse 20, 41–43.
    [Google Scholar]
  23. Malik, R. & Chhibber, S. ( 2009; ). Protection with bacteriophages KØ1 against lethal K. pneumoniae induced burn wound infection in mice. J Microbiol Immunol Infect 42, 134–140.
    [Google Scholar]
  24. Manafi, A., Hashemlou, A., Momeni, P. & Moghimi, H. R. ( 2008; ). Enhancing drugs absorption through third-degree burn wound eschar. Burns 34, 698–702.[CrossRef]
    [Google Scholar]
  25. Matsuzaki, S., Rashel, M., Uchiyma, J., Ujihara, T., Kuroda, M., Ikeuchi, M., Fujieda, M., Wakiguchi, J. & Imai, S. ( 2005; ). Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11, 211–219.[CrossRef]
    [Google Scholar]
  26. Mayhall, C. G. ( 2003; ). The epidemiology of burn wound infections: then and now. Clin Infect Dis 37, 543–550.[CrossRef]
    [Google Scholar]
  27. McVay, C. S., Velásquez, M. & Fralick, J. A. ( 2007; ). Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51, 1934–1938.[CrossRef]
    [Google Scholar]
  28. Moyer, C. A., Brentano, L., Gravens, D. L., Margraf, N. W. & Manafo, W. W. ( 1965; ). Treatment of large human burns with 5 % silver nitrate solution. Arch Surg 90, 812–867.[CrossRef]
    [Google Scholar]
  29. Noronha, C. & Almeida, A. ( 2000; ). Local burn treatment – topical antimicrobial agents. In Annals of Burns and Fire Disasters, vol. XIII, no. 4. Palermo. : Mediterranean Council for Burns and Fire Disasters.
    [Google Scholar]
  30. Ollstein, R. N. & McDonald, C. ( 1980; ). Topical and systemic antimicrobial agents in burns. Ann Plast Surg 5, 386–392.[CrossRef]
    [Google Scholar]
  31. O'Neill, M. A., Vine, G. J., Beezer, A. E., Bishop, A. H., Hadgraft, J., Labetoulle, C., Walker, M. & Bowler, P. G. ( 2003; ). Antimicrobial properties of silver-containing wound dressings: a microcalorimetric study. Int J Pharm 263, 61–68.[CrossRef]
    [Google Scholar]
  32. Ozumba, U. C. & Jiburum, B. C. ( 2000; ). Bacteriology of burn wounds in Enugu, Nigeria. Burns 26, 178–180.[CrossRef]
    [Google Scholar]
  33. Panjeshahin, M. R., Lari, A. R., Talei, A., Shamsnia, J. & Alaghehbandan, R. ( 2001; ). Epidemiology and mortality of burns in the South West of Iran. Burns 27, 219–226.[CrossRef]
    [Google Scholar]
  34. Pruitt, B. A., McManus, A. T., Kim, S. H. & Goodwin, C. W. ( 1998; ). Burn wound infections: current status. World J Surg 22, 135–145.[CrossRef]
    [Google Scholar]
  35. Shukla, I., Tiwari, R. & Agrawal, M. ( 2004; ). Prevalence of extended spectrum β-lactamase producing Klebsiella pneumoniae in a tertiary care hospital. Indian J Med Microbiol 22, 87–91.
    [Google Scholar]
  36. Skurnik, M., Pajunen, M. & Kiljunen, S. ( 2007; ). Biotechnological challenges of phage therapy. Biotechnol Lett 29, 995–1003.[CrossRef]
    [Google Scholar]
  37. Snelling, C. F. T., Ronal, A. R., Waters, W. R., Yaworski, D. S., Drulak, K. & Sunderland, M. ( 1978; ). Comparison of silver sulphadiazine and gentamicin for topical prophylaxis against burn wound sepsis. Can Med Assoc J 119, 466–470.
    [Google Scholar]
  38. Steen, M. ( 1993; ). Review of the use of povidone-iodine (PVP-I) in the treatment of burns. Postgrad Med J 69, S84–S92.
    [Google Scholar]
  39. Taneja, N., Emmanuel, R., Chari, P. S. & Sharma, M. ( 2004; ). A prospective study of hospital-acquired infections in burn patients at a tertiary care referral centre in North India. Burns 30, 665–669.[CrossRef]
    [Google Scholar]
  40. Ulkür, E., Oncül, O., Karagöz, H., Celiköz, B. & Cavuşlu, S. ( 2005; ). Comparison of silver-coated dressing (ActicoatTM), chlorhexidine acetate 0.5 % (Bactigrass®), and silver sulfadiazine 1 % (Silverdin®) for topical antibacterial effect in Pseudomonas aeruginosa-contaminated, full-skin thickness burn wounds in rats. J Burn Care Rehabil 26, 430–433.[CrossRef]
    [Google Scholar]
  41. Verma, V., Harjai, K. & Chhibber, S. ( 2009; ). Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. J Antimicrob Chemother 64, 1212–1218.[CrossRef]
    [Google Scholar]
  42. Vinodkumar, C. S., Kalsurmath, S. & Neelagund, Y. F. ( 2008; ). Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol 51, 360–366.[CrossRef]
    [Google Scholar]
  43. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Reed, E., Ding, L. & other authors ( 2006; ). Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17, 309–317.
    [Google Scholar]
  44. Ward, R. S. & Saffle, J. R. ( 1995; ). Topical agents in burn and wound care. Phys Ther 75, 526–538.
    [Google Scholar]
  45. Wills, Q. F., Kerrigan, C. & Soothill, J. S. ( 2005; ). Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49, 1220–1221.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.018580-0
Loading
/content/journal/jmm/10.1099/jmm.0.018580-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error